0.3600
-0.0040
(-1.10%)
At close: April 17 at 8:08:24 AM GMT+2
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Cash Flow
-23,092
-23,092
-28,566
1,059
-23,561
Investing Cash Flow
-2,308
-2,308
46,449
-46,159
9,745
Financing Cash Flow
35,857
35,857
6,423
1,632
36,930
End Cash Position
46,354
46,354
35,992
11,936
56,277
Interest Paid Supplemental Data
9
9
10
13
13
Capital Expenditure
-565
-565
-674
-413
-340
Issuance of Capital Stock
35,876
35,876
6,426
148
30,865
Repayment of Debt
-54
-54
-54
-32
-20
Repurchase of Capital Stock
-23
-23
-37
-17
-54
Free Cash Flow
-23,657
-23,657
-29,240
646
-23,901
12/31/2021 - 1/3/2000
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
HQ1.MU Oruka Therapeutics Inc. R
7.50
+2.04%
MVR0.BE Medivir AB
0.1372
-2.42%
05Y.MU Vivoryon Therapeutics NV
1.7140
0.00%
HTD.MU Corcept Therapeutics Inc
57.90
-3.60%
PROT Proteonomix, Inc.
0.0000
0.00%
DBV.F DBV Technologies S.A.
1.2520
+1.79%
ICY.HA Incyte Corp
51.16
-0.31%
MVR0.F Medivir AB (publ)
0.1458
-1.88%
RASP Actavia Life Sciences, Inc.
0.0040
0.00%
W1H.F Onco-Innovations Limited
1.0200
-2.86%